New approaches to the adjuvant therapy of colon cancer

Oncologist

Volumn 11, Issue 9, 2006, Pages 973-980

  Benson III, Al B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adjuvant chemotherapy; Colon cancer; Stage II; Stage III

Indexed keywords

BEVACIZUMAB; EDRECOLOMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MOLECULAR MARKER; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONFLICT OF INTEREST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; HUMAN; INCIDENCE; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS; RADIOTHERAPY, ADJUVANT; TUMOR MARKERS, BIOLOGICAL;

EID: 33749839931     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-9-973     Document Type: Review

References (41)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Hobday TJ. An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Clin Colorectal Cancer 2005;5(suppl 1):S11-S18.
3. Baddi L, Benson A 3rd. Adjuvant therapy in stage II colon cancer: current approaches. The Oncologist 2005;10:325-331.
4. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-1425.
5. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797-1806.
6. Green RJ, Metlay JP, Propert K et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 2002;136:261-269.
7. Haller DG, Catalano JS, Macdonald JS et al. Fluorouracil (FU), leucovorin and levamisole adjuvant therapy for colon cancer: five-year final report of INT-0089. Proc Am Soc Clin Oncol 1998;17:256. Abstract 982.
8. Poplin EA, Benedetti JK, Estes NC et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005;23:1819-1825.
9. Chau I, Norman AR, Cunningham D et al. Longitudinal quality of life adjusted survival in a randomized controlled trial comparing sixth months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. Eur J Cancer 2005;41:1551-1559.
10. Chau I, Norman AR, Cunningham D et al. A randomized comparison between 6 months bolus fluorouracil/leucovorin and 12 weeks protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005;16:549-557.
11. Saini A, Norman AR, Cunningham S et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003;16:1859-1865.
12. Armstrong A, Eck SL. EpCAM: a new therapeutic target for an old cancer antigen. Cancer Biol Ther 2003;2:320-326.
13. Punt CJ, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002;360:671-677.
14. Fields ALA, Keller AM, Schwartzberg L et al. Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised North American phase III study. Proc Am Soc Clin Oncol 2002;21:128a. Abstract 508.
15. Wolmark N, Bryant J, Smith R et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 1998;90:1810-1816.
16. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus f luorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J Clin Oncol 2004; 2004 ASCO Annual Meeting Proceedings (Post-Meeting Ed.);22,(14S):3500a.
17. Van Cutsem E, Labianca R, Hossfeld D et al. Randomized phase III trial comparing infused irinotecan / 5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). PETACC 3. Proc Am Soc Clin Oncol 2005;23:8a.
18. Ychou M, Raoul J, Douillard J et al. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Proc Am Soc Clin Oncol 2005;23:3502a
19. Wolmark N, Colangelo L, Wieand S. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer. Semin Oncol 2001;28(1 suppl 1):9-13.
20. Yothers G, Kopec JA, Ganz PA et al. A comparison of quality of life in colon cancer patients receiving adjuvant uracil/ftorafur + leucovorin versus 5-fluorouracil + leucovorin in NSABP C-06. Proc Am Soc Clin Oncol 2005;23:8080a
21. Smith R, Wickerham DL, Wieand HS et al. UFT plus calcium folinate vs 5-FU plus calcium folinate in colon cancer. Oncology (Williston Park) 1999;13(7 suppl 3):44-47.
22. Mamounas EP, Wieand HS, Jones J et al. Future directions in the adjuvant treatment of colon cancer. Oncology (Williston Park) 1997;11(9 suppl 10):44-47.
23. Wolmark N, Wieand HS, Kuebler JP et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. Proc Am Soc Clin Oncol 2005;23:3500a.
24. Hickish T, Boni C, Navarro M et al. FOLFOX4 as adjuvant treatment for stage II colon cancer: subpopulation data from the MOSAIC trial. Proc Am Soc Clin Oncol 2004;22:274a.
25. Andre T, Boni C, Mounedji-Boudiaf L et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
26. de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. Proc Am Soc Clin Oncol 2005;23:3501a.
27. Moertel CG, Fleming TR, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-326.
28. Moertel CG, Fleming TR, Macdonald JS et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995;13:2936-2943.
29. Benson AB 3rd, Catalano PJ, Rao S et al. Thymidylate synthase expression as a predictor for response to 5-fluorouracil-based therapy and survival for patients (pts) with resected colon or advanced colorectal cancer. An ECOG study (Meeting abstract). Proc Am Soc Clin Oncol 1997;16:917a.
30. International Multicentre Pooled Analysis of Colon Cancer B2 Trials Investigators (IMPACT B2). Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999;17:1356-1363.
31. International Multicentre Pooled Analysis of Colon Cancer Trials Investigators (IMPACT). Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-944.
32. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999;17:1349-1355.
33. Schrag D, Rifas-Shiman S, Saltz L et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002;20:3999-4005.
34. Le Voyer TE, Sigurdson ER, Hanlon AL et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;15:2912-2919.
35. Compton C, Fenoglio-Preiser CM, Pettigrew N et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000;88:1739-1757.
36. Yarbro JW, Page DL, Fielding LP et al. American Joint Committee on Cancer prognostic factors consensus conference. Cancer 1999;86:2436-2446.
37. Gray RG, Barnwell J, Hills R et al. QUASAR: a randomized study of adjuvant chemotherapy vs observation including 3238 colorectal cancer patients. J Clin Oncol 2004;22(suppl):245a.
38. Figueredo A, Charette ML, Maroun J et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group. J Clin Oncol 2004;22:3395-3407.
39. Benson A 3rd, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-3419.
40. Buyse M, Piedbois P. Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001;28(1 suppl 1):20-24.
41. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-1206.